Skip to main content

Editas, BlueRock combine forces on gene and cell therapy

The companies will combine Editas’ CRISPR/Cas9 gene editing technology and BlueRock’s stem cell platform in the hopes of engineering stem cells.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.